Resources for healthcare professionals

Hear from William Lumry, MD, a prescriber of ORLADEYO^®

Click or tap the thumbnail to play the video.

Hear from Amar Dixit, MD, a prescriber of ORLADEYO

Click or tap the thumbnail to play the video.

Orladeyo Brochure Thumbnail

Healthcare professional brochure

Learn more about ORLADEYO

Download

Start form

Get your patients started on ORLADEYO.

Download

Tools and resources for your patients

Hear from Leah, a real ORLADEYO patient

Click or tap the thumbnail to play the video.

Hear from Kissa, a real ORLADEYO patient

Click or tap the thumbnail to play the video.

Hear from Kurtis, a real ORLADEYO patient

Click or tap the thumbnail to play the video.

Hear from Angel, a real ORLADEYO patient

Click or tap the thumbnail to play the video.

Hear from Le'ah, a real ORLADEYO patient

Click or tap the thumbnail to play the video.

Hear from Daryl, father and caregiver to Le'ah, a real ORLADEYO patient

Click or tap the thumbnail to play the video.

Hear from Natalie, mother and caregiver to Le'ah, a real ORLADEYO patient

Click or tap the thumbnail to play the video.

ORLADEYO^® (berotralstat) resources

Patient Brochure Thumbnail

ORLADEYO patient brochure

Help your patients learn more about ORLADEYO.

Download

Descargar

Doctor Discussion Guide Thumbnail

ORLADEYO discussion guides

Download the discussion guide that best describes where your patient is in his/her journey and use it to talk about whether ORLADEYO could be right for him/her.

For patients not yet taking a prophylactic therapy

Download

For patients currently taking a prophylactic therapy

Download

Mentor Brochure Thumbnail

ORLADEYO mentor program brochure

Introduce your patients to the mentor program so that they can connect with an ORLADEYO mentor.

Download

ORLADEYO patient programs

Help your patients stay informed by directing them to sign up for a virtual or in-person educational program about ORLADEYO.

Sign up

Smartphone Thumbnail

ORLADEYO text message reminders

Let your patients know that they can sign up to receive daily text message reminders to take their ORLADEYO.

Sign up

Connect with us

Connect with us on Facebook and Instagram for the latest information, tips, and guidance on ORLADEYO.

Follow us on Facebook

Follow us on Instagram

Hereditary angioedema (HAE) resources

US Hereditary Angioedema Association (HAEA)

Direct your patients to the HAEA for information on community involvement as well as HAE educational resources.

Visit site

Interested in meeting?

Request a meeting with a representative to learn more about ORLADEYO

Request a rep

Sign up

Sign up to receive updates on ORLADEYO and information on hereditary angioedema (HAE)

Stay informed

INDICATION

ORLADEYO® (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.

Limitations of use
The safety and effectiveness of ORLADEYO for the treatment of acute HAE attacks have not been established. ORLADEYO should not be used for the treatment of acute HAE attacks. Additional doses or dosages of ORLADEYO higher than 150 mg once daily are not recommended due to the potential for QT prolongation.

IMPORTANT SAFETY INFORMATION

An increase in QT prolongation was observed at dosages higher than the recommended 150 mg once-daily dosage and was concentration dependent.

The most common adverse reactions (≥10% and higher than placebo) in patients receiving ORLADEYO were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease.

A reduced dosage of 110 mg taken orally once daily with food is recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C) and in patients taking chronically administered P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP) inhibitors (eg, cyclosporine).

Berotralstat is a substrate of P-gp and BCRP. P-gp inducers (eg, rifampin, St. John’s wort) may decrease berotralstat plasma concentration, leading to reduced efficacy of ORLADEYO. The use of P-gp inducers is not recommended with ORLADEYO.

ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index that are predominantly metabolized by CYP2D6 or CYP3A4, appropriate monitoring and dose titration is recommended. ORLADEYO at a dose of 300 mg is a P-gp inhibitor. Appropriate monitoring and dose titration is recommended for P-gp substrates (eg, digoxin) when coadministering with ORLADEYO.

The safety and effectiveness of ORLADEYO in pediatric patients <12 years of age have not been established.

There are insufficient data available to inform drug-related risks with ORLADEYO use in pregnancy. There are no data on the presence of berotralstat in human milk, its effects on the breastfed infant, or its effects on milk production.

To report SUSPECTED ADVERSE REACTIONS, contact BioCryst Pharmaceuticals, Inc. at 1-833-633-2279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

INDICATION

ORLADEYO® (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.

Limitations of use
The safety and effectiveness of ORLADEYO for the treatment of acute HAE attacks have not been established. ORLADEYO should not be used for the treatment of acute HAE attacks. Additional doses or dosages of ORLADEYO higher than 150 mg once daily are not recommended due to the potential for QT prolongation.

IMPORTANT SAFETY INFORMATION

An increase in QT prolongation was observed at dosages higher than the recommended 150 mg once-daily dosage and was concentration dependent.

The most common adverse reactions (≥10% and higher than placebo) in patients receiving ORLADEYO were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease.

A reduced dosage of 110 mg taken orally once daily with food is recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C) and in patients taking chronically administered P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP) inhibitors (eg, cyclosporine).

Berotralstat is a substrate of P-gp and BCRP. P-gp inducers (eg, rifampin, St. John’s wort) may decrease berotralstat plasma concentration, leading to reduced efficacy of ORLADEYO. The use of P-gp inducers is not recommended with ORLADEYO.

ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index that are predominantly metabolized by CYP2D6 or CYP3A4, appropriate monitoring and dose titration is recommended. ORLADEYO at a dose of 300 mg is a P-gp inhibitor. Appropriate monitoring and dose titration is recommended for P-gp substrates (eg, digoxin) when coadministering with ORLADEYO.

The safety and effectiveness of ORLADEYO in pediatric patients <12 years of age have not been established.

There are insufficient data available to inform drug-related risks with ORLADEYO use in pregnancy. There are no data on the presence of berotralstat in human milk, its effects on the breastfed infant, or its effects on milk production.

To report SUSPECTED ADVERSE REACTIONS, contact BioCryst Pharmaceuticals, Inc. at 1-833-633-2279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

The content on this website is intended for US healthcare professionals.

I am a healthcare professional

Yes No

You are now leaving this site.